<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01171326</url>
  </required_header>
  <id_info>
    <org_study_id>005-10LND /FX2010-01</org_study_id>
    <nct_id>NCT01171326</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Safety and Efficacy of Topical Minocycline FXFM244 in Impetigo Patients</brief_title>
  <official_title>A Randomized, Parallel-group, Double Blind, Clinical Trial, to Assess the Safety and Efficacy of Topically Applied FXFM244 Antibiotic Foam in the Treatment of Impetigo</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vyne Therapeutics Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vyne Therapeutics Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Impetigo is a common, highly infectious skin disease caused by bacterial infection and&#xD;
      characterized by crusting skin lesions. It is most common in children, particularly children&#xD;
      in unhealthy living conditions. In adults, it may follow other skin disorders. Impetigo is&#xD;
      caused primarily by the bacteria Streptococcus pyogenes and/or Staphylococcus aureus, which&#xD;
      can also be isolated from impetigo lesions.&#xD;
&#xD;
      This is a pilot phase II study to evaluate the tolerability and safety and to monitor the&#xD;
      clinical efficacy of Topical Minocycline Foam FXFM244 in impetigo patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A randomized, parallel-group, double (Investigator, patient) blind, comparative dose range&#xD;
      finding clinical trial.&#xD;
&#xD;
      The study will involve two treatment groups. Eligible patients will be randomized to receive&#xD;
      either FXFM244 - 1%, FXFM244 - 4% , in a blinded fashion. Patients will be treated twice&#xD;
      daily for 7 days. Following the screening period and baseline visit, study subjects will&#xD;
      return at days 3, 7 and 14. At each visit, patients will be evaluated via lesion count,&#xD;
      global assessment tolerability and safety.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2010</start_date>
  <completion_date type="Actual">April 2012</completion_date>
  <primary_completion_date type="Actual">March 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Decrease in lesion count</measure>
    <time_frame>7 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The severity of the overall impetigo condition will be measured at baseline and at all follow-up visits. The severity will be assessed and graded based on the scales for Investigator's Global Assessment and bacteriological testing.</measure>
    <time_frame>Days 3, 7 and 14</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Impetigo</condition>
  <arm_group>
    <arm_group_label>Topical Minocycline Foam FXFM244 - 4%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Minocycline Foam FXFM244 - 4%</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Topical Minocycline Foam FXFM244 - 1%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Minocycline Foam FXFM244 - 1%</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Topical Minocycline Foam FXFM244</intervention_name>
    <description>FXFM244 - 1%, FXFM244 - 4% to be applied twice daily during 7 days</description>
    <arm_group_label>Topical Minocycline Foam FXFM244 - 1%</arm_group_label>
    <arm_group_label>Topical Minocycline Foam FXFM244 - 4%</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with clinical diagnosis of pure impetigo, impetigo contagiosa, or&#xD;
             uncomplicated blistering impetigo&#xD;
&#xD;
          -  Patients 2 years of age or older, and in general good health&#xD;
&#xD;
          -  Patients with no less than two lesions and no more than seven lesions, area 0.5x0.5cm.&#xD;
&#xD;
          -  No known medical conditions that, in the Investigator's opinion could interfere with&#xD;
             study participation&#xD;
&#xD;
          -  Patient / Patient's guardian (in the case of children) willing and able to comply with&#xD;
             all requirement of the protocol&#xD;
&#xD;
          -  Patient / Patient's guardian willing and able to give written informed consent prior&#xD;
             to participation in the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Presence of skin diseases at or near the investigational area&#xD;
&#xD;
          -  Immunosuppressed state or other serious systemic disease&#xD;
&#xD;
          -  Signs and/or symptoms of systemic infection&#xD;
&#xD;
          -  Presence of skin infection/disorder not amenable to topical antibacterial treatment&#xD;
             only&#xD;
&#xD;
          -  Presence of secondarily-infected animal/human bite&#xD;
&#xD;
          -  Presence of secondarily infected burn wound&#xD;
&#xD;
          -  Topical or systemic use of medicinal or other products before or during the study&#xD;
             (oral or topical antibiotics, oral or topical corticosteroids and immuno modulators);&#xD;
             or other drugs, which in the Investigators opinion could confound the evaluation of&#xD;
             the effect of the study drugs&#xD;
&#xD;
          -  Known or suspected hypersensitivity to Minocycline or any of the excipients in the&#xD;
             study medication&#xD;
&#xD;
          -  Participation in any other investigational drug study or use of (an) investigational&#xD;
             drug(s) within the 30 days or 5 half-lives (whichever is longer) prior to&#xD;
             randomization&#xD;
&#xD;
          -  Patients previously enrolled/randomized in this study&#xD;
&#xD;
          -  Use of another investigational drug within 30 days prior to entry into this study.&#xD;
&#xD;
          -  Pregnant or lactating women.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Lev Yasmin Clinic</name>
      <address>
        <city>Natanya</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>December 2010</verification_date>
  <study_first_submitted>July 27, 2010</study_first_submitted>
  <study_first_submitted_qc>July 27, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 28, 2010</study_first_posted>
  <last_update_submitted>December 9, 2013</last_update_submitted>
  <last_update_submitted_qc>December 9, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 10, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>topical</keyword>
  <keyword>minocycline</keyword>
  <keyword>foam</keyword>
  <keyword>phase II</keyword>
  <keyword>impetigo</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Impetigo</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Minocycline</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

